Genmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024. In the quarter to June 2026, revenue grew 24.9%, EPS fell 9.26% and free cash flow fell 7.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow GMAB
Genmab A/S Sponsored ADR (GMAB) Altman Z-score
Genmab A/S Sponsored ADR's Altman Z-score for fiscal 2025 is 2.78, in the grey zone (1.81–2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 2.78 | (5.83) |
| FY2024 | 8.61 | (17.51) |
| FY2023 | 26.12 | (18.19) |
| FY2022 | 44.31 | 1.82 |
| FY2021 | 42.48 | (11.78) |
| FY2020 | 54.26 | 0.76 |
| FY2019 | 53.50 | (33.95) |
| FY2018 | 87.45 | (17.23) |
| FY2016 | 104.68 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.11 | — | 0.14 | |
| Retained earnings / total assets | 0.32 | — | 0.45 | |
| EBIT / total assets | 0.08 | — | 0.27 | |
| Market value of equity / total liabilities | 2.72 | — | 1.63 | |
| Sales / total assets | 0.29 | — | 0.29 | |
| Altman Z-score | Grey zone | 2.78 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 3.21 | ||
Z and Z″ put Genmab A/S Sponsored ADR in different zones: grey zone by Z, safe zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ROIV Roivant Sciences Ltd. compare | 28.3× |
| EXEL Exelixis, Inc. compare | 12.7× |
| INSM Insmed, Inc. compare | 9.3× |
| INCY Incyte Corporation compare | 8.6× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 7.3× |
| GMAB Genmab A/S Sponsored ADR | 2.8× |
| ASND Ascendis Pharma A/S compare | 2.0× |
| RPRX Royalty Pharma PLC compare | 1.6× |
| BNTX BioNTech SE Sponsored ADR compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets